Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2005
11/23/2005EP1598076A1 Interleukin 6 production inhibitor
11/23/2005EP1598072A1 Medical drug containing fine particle of noble metal
11/23/2005EP1598071A1 Superoxide anion decomposing agent
11/23/2005EP1598067A1 Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
11/23/2005EP1598065A2 Drugs for improving prognosis of brain injury
11/23/2005EP1597199A1 THERAPEUTIC MALONIC ACID/ACETIC ACID C sb 60 /sb TRI-ADDUCTS OF BUCKMINSTERFULLERENE AND METHODS RELATED THERETO
11/23/2005EP1503754B1 Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
11/23/2005EP1467718B1 Method of treatment of a patient requiring analgesia
11/23/2005EP1446015A4 Remodeling of tissues and organs
11/23/2005EP1383872B1 Genetically modified yt cell line and use thereof
11/23/2005EP1377550B9 Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors
11/23/2005EP1335898B1 Carbamic acid compounds comprising an amide linkage as hdac inhibitors
11/23/2005EP1276497B1 Mixture of defibrotide and g-csf and its use for activating haematopoietic progenitors
11/23/2005EP1183034B1 Modulators of methylation for control of bacterial virulence
11/23/2005EP1165066B1 Use of lipoxin compounds for inhibiting of tnf-alpha initiated neutrophil response
11/23/2005EP1140291B1 Combination chemotherapy comprising a mitotic inhibitor and a mek inhibitor
11/23/2005EP1104294B8 Compositions and methods of treating abnormal cell proliferation
11/23/2005EP1076559B1 Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease
11/23/2005EP1066261B1 Pyridine derivative and pharmaceutical containing the same
11/23/2005EP1021402B1 Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
11/23/2005EP0929311B1 INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
11/23/2005EP0906088B1 Liposomal antineoplaston therapies with markedly improved antineoplastic activity
11/23/2005EP0837939B1 Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods
11/23/2005CN1701116A Probiotic bacterium: lactobacillus fermentum
11/23/2005CN1701068A Novel compounds and their use
11/23/2005CN1701061A New compounds for the inhibition of rotamases and use thereof
11/23/2005CN1700934A Liquid aerosol formulations and aerosol generating devices and methods for generating aerosols
11/23/2005CN1700922A 3, 10, and 12a substituted tetracycline compounds
11/23/2005CN1700917A Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
11/23/2005CN1699383A Novel aryl fructose-1,6-bisphosphatase inhibitors
11/23/2005CN1699343A Polymorphs of donepezil hydrochloride and process for production
11/23/2005CN1698602A Usage of pyrazoline derivant in the drug preparation for preventing and/or treating cell breeding disease
11/23/2005CN1698601A Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
11/23/2005CN1228338C Imidazole derivatives or salts thereof and drugs contg. derivatives or salts
11/23/2005CN1228330C Imidazole derivatives or their salts
11/23/2005CN1228145C Device and method for coating high-efficient ingredient on plants, application thereof and finished product
11/23/2005CN1228087C Medicinal preparation and its prepn. and application
11/23/2005CN1228075C Anti-senescence Chinese traditional medicine
11/23/2005CN1228039C Composition containing N-vinyl iminazole polymer or copolymer and oxidation sensitive hydrophilic active ingredients for cosmetics and/or dermatology
11/23/2005CN1227977C Composition of N-phenyl-N'-benzoyl carbamide derivant and stem protein compound for preventing vermin
11/22/2005US6967248 Crystalline forms of meloxicam and processes for their preparation and interconversion
11/22/2005US6967245 Ucp5
11/22/2005US6967237 For use in stimulating growth hormone secretion
11/22/2005US6967218 Pravastatin pharmaceutical formulations and methods of their use
11/22/2005US6967214 Inhibitors of IMPDH enzyme
11/22/2005US6967204 Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors
11/22/2005US6967203 Use of pyridoindolone derivatives for preparing anticancer medicines
11/22/2005US6967201 Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
11/22/2005US6967199 Substituted diamine derivatives useful as motilin antagonists
11/22/2005US6967197 Also used in production of tumor necrosis factor alpha
11/22/2005US6967089 Delivery system for porcine somatotropin
11/22/2005US6967020 Oxygen carrier system, artificial oxygen carrier, and reducing agent
11/22/2005US6967019 Production of pancreatic islet cells and delivery of insulin
11/22/2005CA2068066C Herpesvirus particles and vaccine
11/17/2005WO2005108570A1 Nucleic acid/enzyme complex
11/17/2005WO2005108400A1 Pyridoquinazoline derivatives having heterobicyclic substituents
11/17/2005WO2005108399A1 Imidazopyridine compound
11/17/2005WO2005108389A1 Indole derivatives having piperidine rings
11/17/2005WO2005107805A1 Aβ-PRODUCTION INHIBITOR
11/17/2005WO2005107799A1 REMEDY FOR CANCER CONTAINING ANTI-Necl-5 ANTIBODY AS THE ACTIVE INGREDIENT
11/17/2005WO2005107737A1 Antifatigue composition
11/17/2005WO2005107731A1 Remedies containing vitamin k2 as the active ingredient
11/17/2005WO2004108945A3 Oligonucleotide modulation of cell adhesion
11/17/2005WO2004078140A3 SOLUBLE HYALURONIDASE GLYCOPROTEIN (sHASEGP), PROCESS FOR PREPARING THE SAME, USES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF
11/17/2005WO2003042399A8 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
11/17/2005WO1997049725A9 Modified factor viii
11/17/2005US20050256317 Reacting a 5-thio-D-aldohexopyranose derivative with a hydroxyaromatic compound in the presence of a phosphine and an azo reagent; Mitsunobu reaction conditions; useful as an sodium-dependent glucose transporter (SGLT2) inhibitor; beta-selective glycosylation
11/17/2005US20050256315 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
11/17/2005US20050256308 Spiro compounds, medicinal compositions containing the same and intermediates of the compounds
11/17/2005US20050256302 Novel peptides having camp producing activity
11/17/2005US20050256207 Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
11/17/2005US20050256205 prepared by dissolving Venlafaxine in an organic solvent to form a solution at elevated temperature, adding seeding crystals, cooling the solution, and separating the crystalline polymorph; storage stability
11/17/2005US20050256201 Phenethanolamine derivatives
11/17/2005US20050256186 Prevention of and countermeasures against mitochondrial disease
11/17/2005US20050256176 Sulphonamide derivatives and their use as tace inhibitors
11/17/2005US20050256172 1-(3-Pyridyl-2-(N-(2-(3,4-dichlorophenyl)ethyl-N-propylamino)ethanol and a dihydrobromide salt; ligands of sigma receptors; sterol Delta 7,8-isomerase inhibitors; anticholesterol agents; antilipemic agents; hypercholesterolemia and hyperlipemia; side effect reduction due to more targeted action
11/17/2005US20050256171 Pyrrolidine derivatives as tryptase inhibitors
11/17/2005US20050256166 Nitrogen-containing compounds
11/17/2005US20050256160 Beta-alanine derivatives and the use thereof
11/17/2005US20050256148 Topoisomerase I inhibitors; improved stability, water solubility, toxicity; anticancer agents; camptothecins bearing an oxime group in position 7; 7-tert-butoxyiminomethyl-20-O-(4-trimethyl-ammonium-3-hydroxy)butanoyl-camptothecin bromide; parasitic or viral infections
11/17/2005US20050256141 Remedies for glomerular diseases
11/17/2005US20050256140 Condensed pyridines and pyrimidines with tie2 (tek) activity
11/17/2005US20050256122 Substituted pyridazinones
11/17/2005US20050256119 selective serotonine (5-HT) reuptake inhibitor activity in combination with additional alpha 2-adrenocptor antagonist activity; To treat anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia without being sedative
11/17/2005US20050256117 Ophthalmic compositions for treating ocular hypertension
11/17/2005US20050256110 Cyanopyrroles
11/17/2005US20050256108 avoid the adverse side effects associated with non-selective receptor interactions; 1-(4-Fluorobenzyl)-2-(4-methoxybenzyl)-8-methyl-1,2,8-triaza-spiro[4.5]decan-3-one; 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; schizophrenia, psychosis, migraine, hypertension
11/17/2005US20050256103 Indole derivative having piperidine ring
11/17/2005US20050256093 Branched polyamine steroid derivatives
11/17/2005US20050256092 Antipsoriatic agent
11/17/2005US20050256090 Comprises as an active ingredient a sulphostin-related compound such as 3(S)-amino-1-((S)-amino(sulfoamino)-phosphinyl)-2-piperidone
11/17/2005US20050256079 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
11/17/2005US20050256066 Fredericamycin derivatives
11/17/2005US20050256053 Combined use of a GLP-1 compound and another drug for treating dyslipidemia
11/17/2005US20050256051 Nuclear receptor-mediated introduction of a PNA into cell nuclei
11/17/2005US20050256034 Dioxolane analogs for improved inter-cellular delivery
11/17/2005US20050256033 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
11/17/2005US20050255593 Bone marrow stromal cell-derived schwann cells
11/17/2005US20050255576 PGDS inhibitor; antiallergies, sleep control, antiobesity and brain wound healing; Crystals of a complex of human origin hematopoietic prostaglandin D synthase, glutathione and a substrate analog or an inhibitor
11/17/2005US20050255573 An in vitro method of maintaining a mouse or human pluripotent cell in a pluripotent state by increasing expression of a gene that encodes a factor which acts intracellularly and maintainspluripotency, where the factor is a polypeptide of the sequence of SEQ ID NO: 4; cultures
1 ... 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 ... 1564